Apoptosis-inducing factor

• US 7,371,834 B2
• Filed: 12/02/2002
• Issued: 05/13/2008
• Est. Priority Date: 11/23/1998
• Status: Expired due to Fees

• Current Assignee: Amgen Inc., Centre National De La Recherche Scientifique
• Original Assignee: Amgen Inc., Centre National De La Recherche Scientifique
• Inventors: Snow, Bryan E. L., Penninger, Josef M., Susin, Santos A., Zamzami, Naoufal, Siderovski, David Peter, Kroemer, Guido P.
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Aeder; Sean E
• Application Number:
  US10/308,936
• Publication Number:
  US 20030211514A1
• Time in Patent Office: 1,989 Days
• Field of Search: 530/350, 514/1, 536/23.1
• US Class Current: 536/23.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4747 Apoptosis related proteins

Abstract

The present invention related generally novel mammalian apoptosis-inducing factors, polynucleotides encoding such factors and methods related thereto.

Claims

1. An isolated purified human apoptosis-inducing factor, wherein the human apoptosis-inducing factor comprises the amino acid sequence set out in either SEQ ID NO:

8 or SEQ ID NO;

9.

6. The isolated purified human apoptosis-inducing factor of claim 1 or claim 5, wherein the human apoptosis-inducing factor is purified from the biological fluid of a human subject.

7. The isolated purified human apoptosis-inducing factor of claim 6, wherein the human biological fluid is selected from the group consisting of plasma, serum and urine.

8. The isolated purified human apoptosis-inducing factor of claim 6, wherein the human subject overexpresses human apoptosis-inducing factor.

9. The isolated purified human apoptosis-inducing factor of claim 6, wherein the human subject has a neurodegenerative disease.

10. The isolated purified human apoptosis-inducing factor of claim 9, wherein the neurodegenerative disease is selected from the group consisting of neurodegeneration due to stroke, Alzheimer'"'"'s disease, Parkinson'"'"'s disease and amyotrophic lateral sclerosis.

11. The isolated purified human apoptosis-inducing factor of claim 1, further comprising a water-soluble polymer.

12. The isolated purified human apoptosis inducing factor of claim 1, wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol (PEG), monomethoxy-polyethylene glycol, a propylene glycol homopolymer, polypropylene oxide/ethylene oxide copolymer, a polyethylated polyol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6, -trioxane, an ethylene/maleic anhydride copolymer, a homopolymer of polyamino acids, a copolymer of polyamino acids, poly(n-vinyl pyrrolidone)-polyethylene glycol, and polyvinyl alcohol.

2. A composition comprising an isolated purified mammalian apoptosis-inducing factor polypeptide that is not inhibited by Z-VAD fmk, wherein said apoptosis-inducing factor polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

8 or SEQ ID NO;

9.

3. The composition according to claim 2, wherein the mammalian apoptosis-inducing factor is a human apoptosis-inducing factor, and wherein the human apoptosis-inducing factor comprises the amino acid sequence set out in either SEQ ID NO:

8 or SEQ ID NO;

9.

4. A composition comprising an isolated purified human apoptosis inducing factor, wherein the human apoptosis-inducing factor comprises the amino acid sequence set out in either SEQ ID NO:

8 or SEQ ID NO;

9, and a pharmaceutically acceptable carrier, diluent and/or adjuvant.

5. An isolated purified human apoptosis-inducing factor, wherein the human apoptosis-inducing factor comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

8 or SEQ ID NO;

9.